BioSci Capital Partners
Contributor since: 2013
Company: Dr. tran biosci
Latest Articles
Exelixis: Robust Growth Ahead For Cabozantinib
Galmed: A Deep-Dive Analysis Of The ARREST Trial
Solid Biosciences: A Classic Story Of Opportunistic Investing
Ziopharm: Elucidating The Regeneron Partnership For Glioblastoma
Tesaro: In The Middle Of A Difficulty Is An Opportunity
Portola: A Strong Earnings Report That Foretells Much More Fortunes
CytomX: A Growth Stock Trading At A Bargain
IBI Reports On Vericel: Strong Earnings And Promising Prospects
IBI Research On Exelixis: A Stellar Growth Stock With Many Developments
IBI Research On Regenxbio: More Stellar RGX-314 Clinical Outcomes
Atara: Forecasting The Upcoming Clinical Binary Of Tab-Cel
Crispr: Elucidating The Prospects Of The Clinical Hold Removal
Aimmune: To Capture The Vast Food Allergy Market
Vanda: A Grower Operating At An Inflection
Regenxbio (Part IV): Elucidating The Prospects Of The AMD Franchise
Omeros: Substantial Unlocked Value In The GPCR Franchise
Sesen: Positive Unfolding Clinical Development Ahead
Amicus: More Upside For Galafold
Akcea Therapeutics: How To Profit On The Waylivra CRL?
Omeros: Another Win For OMS-721
Esperion: Strong Data To Capture The High Cholesterol Market
Conatus: Elucidating The Upcoming Binary Catalyst For Emricasan
NuCana: Explicating The Prospects Of A Novel Approach To Managing Cancers
Sangamo (Part V): Assessing The Prospects Of SB-913
Global Blood Therapeutics: Iclacumab To Deliver The Pipeline Synergy With Voxelotor
Ocular Therapeutix: Elucidating The Upcoming Regulatory Binary
Strata Skin Sciences: Will This Be A Successful Turnaround In The Making?
Exelixis: Elucidating The Upcoming Clinical Binary For Cabozantinib
Nephros: HemoCleanse Partnership To Deliver Further Upside
Nektar: A Rare Opportunity For Long-Term Investors
Omeros: Powerful Catalysts To Catapult The Shares To A New High
Mustang Bio: Prudent Expansion Into Gene Therapy